MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

27.22 +0.03 (+0.11%)
Streaming Delayed Price Updated: 3:02 PM EDT, Apr 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
The Trillion-Dollar Treatment: A Deep Dive into Eli Lilly and Company (LLY)
As of April 2, 2026, Eli Lilly and Company (NYSE:LLY) stands as the preeminent titan of the global healthcare sector. Historically recognized as a steady, century-old pharmaceutical giant, the company... 
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
3 Monster Dividend Stocks to Hold for the Next 10 Years ↗
These are great and steady income providers for your portfolio. 
Via The Motley Fool
News headline image
Pfizer, BioNTech Hit Pause On COVID Shot Trial As Enrollment Falls Flat ↗
Pfizer & BioNTech halt recruitment for a major U.S. COVID vaccine trial for adults 50–64 due to low enrollment. Read the latest updates. 
Via Benzinga
Pfizer Inc. (NYSE:PFE) Shows Strong Technical Setup for Potential Breakout ↗
Via Chartmill
News headline image
Oric Pharma Misses The 'Best-In-Class' Boat Vs. Pfizer — And Plunges ↗
The company said its prostate cancer drug showed comparable effectiveness to a rival in the class. 
Via Investor's Business Daily
Which S&P500 stocks are the most active on Tuesday? ↗
Via Chartmill
News headline image
Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility
In a trading session characterized by sharp declines across the technology and industrial sectors, the healthcare industry emerged as a resilient fortress on March 31, 2026. While the broader S&P 500... 
Via MarketMinute
Topics Economy Intellectual Property Stocks
News headline image
Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability
As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the... 
Via Finterra
Topics Initial Public Offering
News headline image
Prediction: Buying Pfizer Stock Today Could Set You Up for Life ↗
Pfizer is behind Eli Lilly and Novo Nordisk in the GLP-1 race, but long-term investors shouldn't count the company out. 
Via The Motley Fool
Topics Intellectual Property
News headline image
1 Reason This Biotech Stock Could Triple Before Year-End ↗
This little-known biotech could have a big hit on its hands with VK2735, a GLP-1 weight loss drug candidate. 
Via The Motley Fool
News headline image
Is Now the Time to Buy Salesforce? Here's What the Numbers Reveal ↗
Salesforce's numbers seem to add up to the stock being a solid pick. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Could Buying Eli Lilly Today Set You Up for Life? ↗
Eli Lilly is leading the GLP-1 market, and investors are enthralled with the stock. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data
CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ:SRPT) skyrocketed 34.98% in heavy trading today, marking the biotech giant's most explosive single-day gain in over two years.... 
Via MarketMinute
News headline image
Is Pfizer Stock a Buy After This Win? ↗
Good news has been scarce for this beaten-down drugmaker. 
Via The Motley Fool
News headline image
The $6.7 Billion Pivot: A Deep Dive into Terns Pharmaceuticals (TERN) and the Merck Acquisition
On this Wednesday, March 25, 2026, the biotechnology sector has been electrified by the announcement that Merck & Co. (NYSE: MRK) will acquire Terns Pharmaceuticals, Inc. (NASDAQ: TERN) in an all-cash... 
Via Finterra
Topics Initial Public Offering Intellectual Property World Trade
News headline image
Sarepta Therapeutics (SRPT) at a Crossroads: A 2026 Deep Dive into the Future of Genetic Medicine
As of March 25, 2026, Sarepta Therapeutics (NASDAQ: SRPT) stands at a pivotal, albeit bruising, crossroads in the history of genetic medicine. Once the darling of the biotechnology sector for its... 
Via Finterra
Topics Economy Intellectual Property Retirement
News headline image
Merck & Co. (MRK) 2026 Analysis: Navigating the Keytruda Cliff with Pipeline-Driven Resilience
As of March 25, 2026, Merck & Co., Inc. (NYSE: MRK) stands at a pivotal crossroads in its 135-year history. Known globally as a titan of oncology and vaccines, the Rahway, New Jersey-based... 
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
Stay informed about the most active stocks in the S&P500 index on Tuesday's session. ↗
Via Chartmill
News headline image
Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer To Rally More Than 34%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
Analysts change ratings & price targets for HSCS, ONDS, STRO, PFE, HST, CABA, INSM, PVH. See full list & how others rate each stock. 
Via Benzinga
News headline image
Bristol-Myers Squibb Shares Jump 3.3% on Robust 2026 Guidance and High Dividend Yield
Shares of pharmaceutical giant Bristol-Myers Squibb (NYSE:BMY) climbed 3.3% in early trading on Monday, March 23, 2026, after the company issued a surprisingly robust financial outlook for the fiscal... 
Via MarketMinute
Topics Economy Initial Public Offering Intellectual Property
News headline image
Pfizer Stock Is Doing Something It Hasn't Done Since 2022 ↗
Up until recently, the stock has been a chronic underperformer. 
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
5 High-Yield Stocks to Shield Your Portfolio From the Storm ↗
Via MarketBeat
News headline image
Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive ↗
Valneva stock drops after Phase 3 Lyme vaccine misses primary endpoint; secondary data shows efficacy as Pfizer backs regulatory submissions. 
Via Benzinga
News headline image
Valneva, Venture Global And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
Dow futures up 1000 points. Valneva stock falls in pre-market. Pfizer and Valneva announce Phase 3 results for Lyme disease vaccine. Other stocks also down. 
Via Benzinga
Topics Stocks
News headline image
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial
From Pfizer Inc.
Via Business Wire
News headline image
Have $500? 2 Healthcare Stocks Long-Term Investors Should Buy Right Now ↗
You can get in on these market giants for bargain prices today. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Unpopular Stocks That Should Get More Attention and 1 We Avoid
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t... 
Via StockStory
Topics Supply Chain
News headline image
Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC
From Pfizer Inc.
Via Business Wire
News headline image
My Top 3 Drug Stocks for March 2026 ↗
These companies have impressive track records of navigating the biggest challenges in their industry. 
Via The Motley Fool
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story